These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38953946)

  • 1. Low-dose glucocorticoid increase the risk of fracture in postmenopausal women with low bone mass: a retrospective cohort study.
    Park SY; Ahn SH; Bae GH; Jang S; Kwak MK; Kim HY; Kim SH;
    Osteoporos Int; 2024 Oct; 35(10):1779-1787. PubMed ID: 38953946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Systemic Glucocorticoid Use on Fracture Risk: A Population-Based Study.
    Koh JW; Kim J; Cho H; Ha YC; Kim TY; Lee YK; Kim HY; Jang S
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):562-570. PubMed ID: 32981298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low bone mineral density, but not epidural steroid injection, is associated with fracture in postmenopausal women with low back pain.
    Yi Y; Hwang B; Son H; Cheong I
    Pain Physician; 2012; 15(6):441-9. PubMed ID: 23159959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative ability of trabecular bone score over bone mineral density for vertebral and fragility fracture in patients treated with long-term and low-dose glucocorticoid.
    Lee KA; Kim J; Kim HJ; Kim HS
    Int J Rheum Dis; 2021 Aug; 24(8):1053-1060. PubMed ID: 34184827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD; Martineau P; Bryanton M; Lix LM
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K; Fukuda H
    Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalent vertebral fractures and minor vertebral deformities analyzed by vertebral fracture assessment (VFA) increases the risk of incident fractures in postmenopausal women: the FRODOS study.
    Kanterewicz E; Puigoriol E; Rodríguez Cros JR; Peris P
    Osteoporos Int; 2019 Oct; 30(10):2141-2149. PubMed ID: 31123788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-treated Rheumatic Disorders.
    Ward LM; Ma J; Robinson ME; Scharke M; Ho J; Houghton K; Huber A; Scuccimarri R; Barsalou J; Roth J; Shenouda N; Matzinger MA; Lentle B; Jaremko JL; Koujok K; Watanabe Duffy K; Stein R; Sbrocchi AM; Rodd C; Miettunen PM; LeBlanc CMA; Larche M; Jurencak R; Cummings EA; Couch R; Cabral DA; Atkinson S; Alos N; Sykes E; Konji VN; Rauch F; Siminoski K; Lang B
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e5195-e5207. PubMed ID: 34232311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overweight/obesity and underweight are both risk factors for osteoporotic fractures at different sites in Japanese postmenopausal women.
    Tanaka S; Kuroda T; Saito M; Shiraki M
    Osteoporos Int; 2013 Jan; 24(1):69-76. PubMed ID: 23229467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausal women over 10 years: the Japanese Population-based Osteoporosis (JPOS) Cohort Study.
    Tamaki J; Iki M; Kadowaki E; Sato Y; Chiba Y; Akiba T; Matsumoto T; Nishino H; Kagamimori S; Kagawa Y; Yoneshima H;
    Osteoporos Int; 2013 Mar; 24(3):887-97. PubMed ID: 22885773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome.
    Phan V; Blydt-Hansen T; Feber J; Alos N; Arora S; Atkinson S; Bell L; Clarson C; Couch R; Cummings EA; Filler G; Grant RM; Grimmer J; Hebert D; Lentle B; Ma J; Matzinger M; Midgley J; Pinsk M; Rodd C; Shenouda N; Stein R; Stephure D; Taback S; Williams K; Rauch F; Siminoski K; Ward LM;
    Osteoporos Int; 2014 Feb; 25(2):627-37. PubMed ID: 23948876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis treatment considerations based upon fracture history, fracture risk assessment, vertebral fracture assessment, and bone density in Canada.
    Leslie WD; Lix LM; Binkley N
    Arch Osteoporos; 2020 Jun; 15(1):93. PubMed ID: 32577922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of medications and epidural steroid injections on fractures in postmenopausal women with osteoporosis.
    Kim M; Yang YH; Son HJ; Huh J; Cheong Y; Kang SS; Hwang B
    Medicine (Baltimore); 2019 Jun; 98(26):e16080. PubMed ID: 31261519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial Bone Density Measurement and Incident Fracture Risk Discrimination in Postmenopausal Women.
    Crandall CJ; Larson J; Wright NC; Laddu D; Stefanick ML; Kaunitz AM; Watts NB; Wactawski-Wende J; Womack CR; Johnson KC; Carbone LD; Jackson RD; Ensrud KE
    JAMA Intern Med; 2020 Sep; 180(9):1232-1240. PubMed ID: 32730575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vertebral fracture assessment by dual-energy X-ray absorptiometry along with bone mineral density in the evaluation of postmenopausal osteoporosis.
    Shetty S; John B; Mohan S; Paul TV
    Arch Osteoporos; 2020 Feb; 15(1):25. PubMed ID: 32095943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.
    Angeli A; Guglielmi G; Dovio A; Capelli G; de Feo D; Giannini S; Giorgino R; Moro L; Giustina A
    Bone; 2006 Aug; 39(2):253-9. PubMed ID: 16574519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
    Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
    Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.